Friday, June 24, 2022

NEWR/RXRX/BEAM










 NEWR/RXRX/BEAM

NYSE: NEWR

  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

    More about Recursion Pharmaceutical

  • xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx


  • https://finance.yahoo.com/quote/beam
  • 52 Week Range27.77 - 138
  • .52Volume282,631
  • Avg. Volume1,328,369
  • Market Cap3.04B
    Beta (5Y Monthly)1.60

  • imilar to BEAM

    SymbolLast PriceChange% Change
    NTLA

    Intellia Therapeutics, Inc.

    54.56+3.80+7.48%
    EDIT

    Editas Medicine, Inc.

    13.61+0.11+0.81%
    CRBU

    Caribou Biosciences, Inc.

    6.04+0.15+2.55%
    VERV

    Verve Therapeutics, Inc.

    16.00-0.18-1.11%
    FATE

    Fate Therapeutics, Inc.

    26.45+0.84+3.30%
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

No comments:

Post a Comment